Last reviewed · How we verify
Bevacizumab (Bev)
Bevacizumab is a monoclonal antibody that blocks vascular endothelial growth factor (VEGF), preventing tumor blood vessel formation and starving tumors of oxygen and nutrients.
Bevacizumab is a monoclonal antibody that blocks vascular endothelial growth factor (VEGF), preventing tumor blood vessel formation and starving tumors of oxygen and nutrients. Used for Metastatic colorectal cancer (in combination with chemotherapy), Metastatic non-small cell lung cancer (in combination with chemotherapy), Metastatic breast cancer (in combination with chemotherapy).
At a glance
| Generic name | Bevacizumab (Bev) |
|---|---|
| Also known as | HLX04 |
| Sponsor | Eli Lilly and Company |
| Drug class | VEGF inhibitor (monoclonal antibody) |
| Target | VEGF (Vascular Endothelial Growth Factor) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
Bevacizumab binds to circulating VEGF, a key signaling protein that promotes angiogenesis (new blood vessel growth). By neutralizing VEGF, the drug inhibits the formation of new blood vessels that tumors require to grow and metastasize. This anti-angiogenic mechanism reduces tumor perfusion and can slow or halt cancer progression.
Approved indications
- Metastatic colorectal cancer (in combination with chemotherapy)
- Metastatic non-small cell lung cancer (in combination with chemotherapy)
- Metastatic breast cancer (in combination with chemotherapy)
- Glioblastoma (recurrent)
- Metastatic renal cell carcinoma (in combination with interferon-alpha)
- Cervical cancer (in combination with chemotherapy)
Common side effects
- Hypertension
- Proteinuria
- Hemorrhage (all grades)
- Thromboembolism
- Gastrointestinal perforation
- Wound healing complications
- Fatigue
- Diarrhea
- Congestive heart failure
Key clinical trials
- Bevacizumab Plus FSRT Versus Hippocampus-Avoidant WBRT in Lung Adenocarcinoma With Extensive Brain Metastases (PHASE3)
- PD-1 (Programmed Death-1) Versus PD-L1 (Programmed Death-ligand 1) Immune Check Point Inhibitors Combined With Chemotherapy, With or Without Bevacizumab, In Patients With Metastatic, Persistent Or Recurrent Cervical Cancer (PHASE2, PHASE3)
- PARP (Poly (ADP-ribose) Polymerase) Inhibitor With or Without Angiogenesis Inhibitor in Homologous Recombination Deficient Primary Ovarian Cancer, Fallopian-Tube Cancer, or Primary Peritoneal Cancer (PHASE2, PHASE3)
- SBRT With Immunotherapy and Atezo-Bev in HCC With Major Portal Vein Thrombosis (PHASE2)
- A Real-World Study to Learn More About the Order of Different Treatments and Their Effects in People With Metastatic Colorectal Cancer Receiving Their Third and Fourth Line of Treatment
- Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer (PHASE1, PHASE2)
- Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer (PHASE1, PHASE2)
- SBRT With Atezo/Bev for HCC (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Bevacizumab (Bev) CI brief — competitive landscape report
- Bevacizumab (Bev) updates RSS · CI watch RSS
- Eli Lilly and Company portfolio CI